Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study

Purpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-reported outcomes (PROs) over 52 weeks.Materials and methods:...

Full description

Saved in:
Bibliographic Details
Main Authors: Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Atopic dermatitis
disease burden
patient-reported outcome measures
quality of life
upadacitinib
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2344589
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2344589

Similar Items